Pharmaceutical formulation comprising cyclosporin and use thereof
AssigneeJagotec AG
InventorsJohannes Wohlrab, Reinhard Neubert, Konstanze Jahn
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical formulation in colloidal form for topical application for the therapy and prophylaxis of pathological changes of the skin and/or integumentary structures of the skin and/or mucous membranes, including mucous membranes of the digestive tract, uro-genital tract and bronchial system and/or conjunctiva, containing a lipophilic phase in a quantity of 1-10% by weight, a mixture of surfactant and co-surfactant in a quantity of 1-50% by weight, a hydrophilic phase in a quantity of 40-80% by weight and, as active ingredient, cyclosporin and/or derivatives thereof in a concentration of 0.1-20% by weight.
Claims7
A method of treatment of inflammatory skin and mucous membrane diseases, comprising the step of topical application of a pharmaceutical formulation in colloidal form to a patient, said pharmaceutical formulation comprising:
- a) a lipophilic phase in a quantity of 1-10% by weight,
- b) a mixture of surfactant, wherein the surfactant comprises polyoxyethylene glycerol fatty acid esters, and co-surfactant, wherein the co-surfactant comprises poloxamers in a quantity of 1-50% by weight, the surfactant/co-surfactant mixture being used in a mass ratio of 2 for the surfactant and 3 for the co-surfactant,
- c) a hydrophilic phase in a quantity of 40-80% by weight, and
- d) as active ingredient, cyclosporin, in a concentration of 0.1-20% by weight.
A method of treatment of atopical dermatitis, comprising the step of topical application of a pharmaceutical formulation in colloidal form to a patient, said pharmaceutical formulation comprising:
- a) a lipophilic phase in a quantity of 1-10% by weight,
- b) a mixture of surfactant, wherein the surfactant comprises polyoxyethylene glycerol fatty acid esters, and co-surfactant, wherein the co-surfactant comprises poloxamers in a quantity of 1-50% by weight, the surfactant/co-surfactant mixture being used in a mass ratio of 2 for the surfactant and 3 for the co-surfactant,
- c) a hydrophilic phase in a quantity of 40-80% by weight, and
- d) as active ingredient, cyclosporin, in a concentration of 0.1-20% by weight.
A method of treatment of psoriasis vulgaris, comprising the step of topical application of a pharmaceutical formulation in colloidal form to a patient, said pharmaceutical formulation comprising:
- a) a lipophilic phase in a quantity of 1-10% by weight,
- b) a mixture of surfactant, wherein the surfactant comprises polyoxyethylene glycerol fatty acid esters, and co-surfactant, wherein the co-surfactant comprises poloxamers in a quantity of 1-50% by weight, the surfactant/co-surfactant mixture being used in a mass ratio of 2 for the surfactant and 3 for the co-surfactant,
- c) a hydrophilic phase in a quantity of 40-80% by weight, and
- d) as active ingredient, cyclosporin, in a concentration of 0.1-20% by weight.
A method of treatment of collagenoscs, chronic wounds, burns, and/or chronically inflammatory skin and mucous membrane diseases, comprising the step of topical application of a pharmaceutical formulation in colloidal form to a patient, said pharmaceutical formulation comprising:
- a) a lipophilic phase in a quantity of 1-10% by weight,
- b) a mixture of surfactant, wherein the surfactant is comprises polyoxyethylene glycerol fatty acid esters, and co-surfactant, wherein the co-surfactant comprises poloxamers in a quantity of 1-50% by weight, the surfactant/co-surfactant mixture being used in a mass ratio of 2 for the surfactant and 3 for the co-surfactant,
- c) a hydrophilic phase in a quantity of 40-80% by weight, and
- d) as active ingredient, cyclosporin, in a concentration of 0.1-20% by weight.
A method of treatment of chronically inflammatory bowel disease, comprising the step of application of a pharmaceutical formulation in colloidal form to a patient as a clyster, said pharmaceutical formulation comprising:
- a) a lipophilic phase in a quantity of 1-10% by weight,
- b) a mixture of surfactant, wherein the surfactant comprises polyoxyethylene glycerol fatty acid esters, and co-surfactant, wherein the co-surfactant comprises poloxamers in a quantity of 1-50% by weight, the surfactant/co-surfactant mixture being used in a mass ratio of 2 for the surfactant and 3 for the co-surfactant,
- c) a hydrophilic phase in a quantity of 40-80% by weight, and
- d) as active ingredient, cyclosporin, in a concentration of 0.1-20% by weight.
A method of treatment of inflammatory diseases of the eye, comprising the step of topical application of a pharmaceutical formulation in colloidal form to a patient, said pharmaceutical formulation comprising:
- a) a lipophilic phase in a quantity of 1-10% by weight,
- b) a mixture of surfactant, wherein the surfactant comprises polyoxyethylene glycerol fatty acid esters, and co-surfactant, wherein the co-surfactant comprises poloxamers in a quantity of 1-50% by weight, the surfactant/co-surfactant mixture being used in a mass ratio of 2 for the surfactant and 3 for the co-surfactant,
- c) a hydrophilic phase in a quantity of 40-80% by weight, and
- d) as active ingredient, cyclosporin, in a concentration of 0.1-20% by weight.
A method of treatment of rejection reactions after transplants, comprising the step of topical application of a pharmaceutical formulation in colloidal form to a patient, said pharmaceutical formulation comprising:
- a) a lipophilic phase in a quantity of 1-10% by weight,
- b) a mixture of surfactant, wherein the surfactant comprises polyoxyethylene glycerol fatty acid esters, and co-surfactant, wherein the co-surfactant comprises poloxamers in a quantity of 1-50% by weight, the surfactant/co-surfactant mixture being used in a mass ratio of 2 for the surfactant and 3 for the co-surfactant,
- c) a hydrophilic phase in a quantity of 40-80% by weight, and
- d) as active ingredient, cyclosporin, in a concentration of 0.1-20% by weight.
Dependencies are inferred from the claim text.